Sat, Nov 29, 2014, 3:59 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Anthera Pharmaceuticals, Inc. (ANTH) Message Board

jennifer_jkarim 14 posts  |  Last Activity: Oct 24, 2014 2:49 PM Member since: May 1, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • I'm looking for sales to be north of a $million for Q3, when released, about the same time this year.

  • Reply to

    96,000 Shares Bought the Last Few Minutes

    by jennifer_jkarim Oct 23, 2014 1:18 PM
    jennifer_jkarim jennifer_jkarim Oct 23, 2014 1:31 PM Flag

    I'm posting FACTS..... you are BASHING...... trying to turn anything that is positive into a negative.
    There were prior missteps at his Company, I don't spin those into negatives.

    I railed against the discounted sale of shares to the Turkish distributor and even posted the email that I sent to GC.

    I call it as it is ..... you are twisting anything that is even remotely positive into a negative.
    How does your wife put up with you, grumpy old man?

  • Reply to

    2 Form 4s Filed for Insider Buys on 10/20

    by jennifer_jkarim Oct 23, 2014 12:39 PM
    jennifer_jkarim jennifer_jkarim Oct 23, 2014 1:25 PM Flag

    Read carefully:
    Imhoff and Hart could have taken cash by selling the shares. They did not.
    In effect, it's like taking the cash, that they were due, and buying shares.
    The cash that hey were entitled to was converted to additional shares.
    The effect of the transaction is that the insiders bought over 40K shares.

  • Took out the .33, pushed the pps over .34.

    Now seanoise can respond that someone sold 96K shares.)))

  • jennifer_jkarim jennifer_jkarim Oct 23, 2014 1:03 PM Flag

    Is the glass always half empty for you?

    The insiders could have sold the shares for cash.
    They did not.
    So in effect, for the cash dividend that they were entitled to, they bought shares.

  • jennifer_jkarim jennifer_jkarim Oct 23, 2014 12:48 PM Flag

    That's the same as taking a cash dividend and then buying shares with the funds.

  • Imhoff bought 39,063 shares
    Hart bought 1,953 shares

    Would they buy at .32 if an offering was coming out at a lower price?
    Food for thought.

    The odds of a partnership have increased immensely.

  • Imhoff who sold monthly is now buying.
    Imhoff would never buy before an offering.
    One can only conclude that the offering has been shelved.

  • jennifer_jkarim by jennifer_jkarim Oct 23, 2014 12:27 PM Flag

    A few good buyers and we're off to the races.

  • Reply to

    I have too many shares to add any more...

    by lobsterpot1989 Oct 3, 2014 12:05 PM
    jennifer_jkarim jennifer_jkarim Oct 11, 2014 2:39 PM Flag

    "Always a better mouse trap" is meaningless.
    Tell that to AAPL shareholders or EXAS shareholders.

    Biotechs are always raising funds. GTHP controls it's own destiny, just like the biotechs. Approval coupled with a partnership will raise the needed funds, together with an earnings flow and cash to develop scans for other cancers.

  • Reply to

    I have too many shares to add any more...

    by lobsterpot1989 Oct 3, 2014 12:05 PM
    jennifer_jkarim jennifer_jkarim Oct 11, 2014 12:05 PM Flag

    If GC can hold off diluting until approval, there is a mandatory exercise of warrants upon the FDA nod.

    I don't see why the US rights can't be partnered prior to approval. Navidea signed up Cardinal Health before their imaging agent got approved. It's done all the time. Heck, Inovio partnered some PRECLINICALS with Roche for $10M plus potential milestones of $400M and royalties. GC has the product of the year plus connections, what's the problem?

    I'm still amazed at the market cap of EXAS which has a pooper scooper test for colorectal cancer which requires poop to be collected and sent to a lab. It's $2 BILLION!!! And GTHP is at $20 million???

    It's time for GC to pull a rabbit out of the hat instead of sheeting in it, as he did with the .30 sale to the Turkish distributor.

  • jennifer_jkarim by jennifer_jkarim Sep 23, 2014 3:29 PM Flag

    Mr. Cartwright,

    When shares are sold at a discount to the market price, everyone loses.
    Had ITEM Medical bought 500,000 shares at .40 ( a small premium), the pps would have gone up.
    ITEM would have made money and shareholders would have profited.

    Selling the shares at .30 tells the markets that the stock is not worth more than .30.
    If the Company is selling shares at .30, why would anyone pay more?

    Please end the cycle of selling shares below market price.
    It only serves to push the stock price lower and it benefits no one.

    Sell shares at a premium and the stock price will go up.
    If the investor is not convinced, guarantee reimbursement of any losses on the shares for a period of time.
    When an investor pays a premium, it signals to the markets that the stock is undervalued and the stock price will rise.

    In the alternative, you can raise funds by issuing rights to shareholders.
    It's non-dilutive.

    Regards,

    Jenn

  • Reply to

    email to GC sent 9/19

    by jennifer_jkarim Sep 23, 2014 3:19 PM
    jennifer_jkarim jennifer_jkarim Sep 23, 2014 3:26 PM Flag

    (continued)

    The stock price was over $2 in 2004. Now with the markets at record highs, GTHP is nearing record lows.
    What expectations should shareholders have for the balance of the year? Will you be offering shares and free warrants at continually lower discounted prices or will you alter the decade long downward spiral?

    Respectfully,

    Jenn

  • jennifer_jkarim by jennifer_jkarim Sep 23, 2014 3:19 PM Flag

    Mr. Cartwright,

    In October 2013, the stock was trading in the .60s when the Company announced a repricing of the outstanding .65 warrants to .40. The stock price promptly dropped into the .40s.

    In September of this year, the stock was near .40 when the Company announced the "investment" by a Turkish distributor at .30 plus free warrants. The stock price promptly dropped to .30.
    Selling a dollar for .75 is not an investment, it's highway robbery.

    If ITEM Medical tried buying 650,000 shares on the open market, their average price would have been closer to .50. So, if they were interested in making an investment, .50 plus the free warrants would have been a fair price. The Company raised $200,000 but shareholders lost $10 million on the price drop from .45 to .30.

    The stock price is not a reflection of the value of the Company. In the discussions with ITEM Medical, did you make a case that the Company is worth $1 per share and that you'd sell them shares at a 50% discount, or .50 plus free warrants?

    The stock closed at .375 today. As a stockholder, I would be thrilled to buy 650,000 shares at .40 ( a premium to the market price), if 325,000 warrants were included.

    A S1 was recently filed for the sale of up to 45 million shares. Will the next sale of shares be at .20?
    Will the downward spiral ever end?

    Paying fees to Olympus for massive dilution of shareholders is preferable to a non-dilutive rights offering to shareholders? You are supposed to be be working for shareholders, not against them.

    The stock should spike on the anticipated FDA approval, which will trigger the exercise of warrants. Is this registration just precautionary, in the event that FDA approval is not received, or will you be pounding the depressed stock price even lower with more discounted offerings before the FDA decision?

    I was hopeful that, with your connections, you would be able to secure funds via an investment, distribution agreement or loan from a large medical device company.

ANTH
2.05+0.0500(+2.50%)Nov 28 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.